No Data
US Stock MarketDetailed Quotes
NKTX Nkarta
Watchlist
4.750
+0.160+3.49% Close 06/02 16:00 ET
5.150+0.400+8.42%
Post 19:58 ET
4.840High4.600Low170.01KVolume
4.680Open4.590Pre Close803.06KTurnover0.57%Turnover RatioLossP/E (TTM)232.44MMarket Cap18.48052wk HighLossP/E (Static)48.93MShares3.12052wk Low0.67P/B142.15MFloat Cap79.160Historical High--Dividend TTM29.93MShs Float3.120Historical Low--Div YieldTTM5.23%Amplitude4.723Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Revenue Breakdown
Business
Unit:USD
NameYOYOperating income%
Single segment--115.39K100.00%
News
Comments
TOP WATCH AH + 4/5 ⚡️⚡️
$C3.ai(AI.US$$BigBear.ai Holdings(BBAI.US$$Butterfly Network(BFLY.US$$BullFrog AI(BFRG.US$$Cardlytics(CDLX.US$$Leonardo DRS, Inc.(DRS.US$$Guardforce AI(GFAI.US$$iBio Inc(IBIO.US$$InflaRx(IFRX.US$$Leju Holdings(LEJU.US$$Multi Ways(MWG.US$$Nkarta(NKTX.US$$Oncternal Therapeutics(ONCT.US$$Secoo(SECO.US$
3
$Nkarta(NKTX.US$ sell and then buy in at cheaper prices and sell again
1
Read more